Home › Research › Cognitive tests and assessment
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Suzanne Samuels Mirra, Albert Heyman, Daniel W. McKeel, S. M. Sumi, Barbara J. Crain, Lorelle Brownlee, F. Stephen Vogel, J. P. Hughes et al.. Neurology, 1991-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects. The protocol provides neuropathologic definitions of such terms as "definite Alzheimer's disease" (AD), "probable AD," "possible AD," and "normal brain" to indicate levels of diagnostic certainty, reduce subjective interpretation, and assure common language. To pretest the protocol, neuropathologists from 15 participating centers entered information on autopsy brains from 142 demented patients clinically diagnosed as probable AD and on eight nondemented patients. Eighty-four percent of the dementia cases fulfilled CERAD neuropathologic criteria for definite AD. As increasingly large numbers of prospectively studied dementia and control subjects are autopsied, the CERAD neuropathology protocol will help to refine diagnostic criteria, assess overlapping pathology, and lead to a better understanding of early subclinical changes of AD and normal aging.
What this study adds
Evidence grade: Low
The CERAD Neuropathology Task Force developed a standardized postmortem protocol providing definitions such as definite, probable, and possible Alzheimer's disease to indicate levels of diagnostic certainty and assure common language. In pretesting, 84% of dementia cases clinically diagnosed as probable Alzheimer's disease met CERAD neuropathologic criteria for definite Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mirra, S. S., Heyman, A., McKeel, D. W., Sumi, S. M., Crain, B. J., Brownlee, L., et al. (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology. https://doi.org/10.1212/wnl.41.4.479
Vancouver
Mirra SS, Heyman A, McKeel DW, Sumi SM, Crain BJ, Brownlee L, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology. 1991. doi:10.1212/wnl.41.4.479. PMID: 2011243.
BibTeX
@article{mirra1991-2011243,
author = {Mirra, Suzanne Samuels and Heyman, Albert and McKeel, Daniel W. and Sumi, S. M. and Crain, Barbara J. and Brownlee, Lorelle and Vogel, F. Stephen and Hughes, J. P. and others},
title = {{The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)}},
journal = {Neurology},
year = {1991},
doi = {10.1212/wnl.41.4.479},
pmid = {2011243},
url = {https://doi.org/10.1212/wnl.41.4.479}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects.
- The protocol provides neuropathologic definitions of such terms as "definite Alzheimer's disease" (AD), "probable AD," "possible AD," and "normal brain" to indicate levels of diagnostic certainty, reduce subjective interpretation, and assure common language.
- To pretest the protocol, neuropathologists from 15 participating centers entered information on autopsy brains from 142 demented patients clinically diagnosed as probable AD and on eight nondemented patients.
- Eighty-four percent of the dementia cases fulfilled CERAD neuropathologic criteria for definite AD.
- As increasingly large numbers of prospectively studied dementia and control subjects are autopsied, the CERAD neuropathology protocol will help to refine diagnostic criteria, assess overlapping pathology, and lead to a better understanding of early subclinical changes of AD and normal aging.
Why it matters
The CERAD Neuropathology Task Force developed a standardized postmortem protocol providing definitions such as definite, probable, and possible Alzheimer's disease to indicate levels of diagnostic certainty and assure common language. In pretesting, 84% of dementia cases clinically diagnosed as probable Alzheimer's disease met CERAD neuropathologic criteria for definite Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 61/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 59 of the 96 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1991 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 4,972 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 134.4 citations a year over 37 year(s) since 1991 |
| Impact for its field and year | 5 / 6 | Cited 28.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 6 / 6 | Cited by 380 other studies in this library |
| Still being cited | 4 / 4 | Cited 493 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 2011243) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 59 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 96 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
380 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Cognitive tests and assessment from nearby years
Also in Cognitive tests and assessment
92 studies in the library are filed under Cognitive tests and assessment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Cognitive tests and assessment hub.